Home/Filings/4/0001739614-24-000033
4//SEC Filing

Eckelman Brendan P. 4

Accession 0001739614-24-000033

CIK 0001739614other

Filed

May 23, 8:00 PM ET

Accepted

May 24, 6:15 PM ET

Size

7.8 KB

Accession

0001739614-24-000033

Insider Transaction Report

Form 4
Period: 2024-05-22
Eckelman Brendan P.
DirectorChief Scientific Officer10% Owner
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-05-22$34.12/sh2,510$85,6416,667 total
    Exercise: $33.63Exp: 2031-01-15Common Stock (2,510 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-05-22$34.12/sh2,500$85,30026,667 total
    Exercise: $23.30Exp: 2033-01-03Common Stock (2,500 underlying)
Footnotes (2)
  • [F1]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
  • [F2]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Issuer

Inhibrx, Inc.

CIK 0001739614

Entity typeother

Related Parties

1
  • filerCIK 0001766433

Filing Metadata

Form type
4
Filed
May 23, 8:00 PM ET
Accepted
May 24, 6:15 PM ET
Size
7.8 KB